AJH: Freeze-dried platelets are a promising alternative for patients with hemorrhagic thrombocytopenia due to hematological malignancies

Thrombus is trehalose-stabilized, freeze-dried group O platelets, with a shelf life of 3 years

Thrombus is trehalose-stabilized, freeze-dried group O platelets, with a shelf life of 3 years

The research team conducted an open-label phase 1 study to study single-dose allogeneic thrombi at 3 dose levels in 3 cohorts.

The research team conducted an open-label phase 1 study to study single-dose allogeneic thrombi at 3 dose levels in 3 cohorts.

The study included 24 patients required for participation and lasted approximately 15 months

The initial dose received by Cohort 1 was approximately 5 times the highest dose used in the previous dose escalation study in healthy volunteers

Of the 24 patients included,12 patients (50%) had a clinically significant increase in platelet count 24 hours after the infusion

The results also show that thrombus can be used for thrombocytopenia in patients with hematological malignancies

Original source:

Ohanian, M.

Ohanian, M.
, Cancelas, JA, Davenport, R.
, Pullarkat, V.
, Hervig, T.
, Broome, C.
, Marek, K.
, Kelly, M.
, Gul, Z.
, Rugg, N.
, Nestheide , S.
, Kinne, B.
, Szczepiorkowski, Z.
, Kantarjian, H.
, Pehta, J.
, Biehl, R.
, Yu, A.
, Aung, F.
, Antebi, B.
and Fitzpatrick, GM (2021) , Freeze-Dried Platelets Are a Promising Alternative in Bleeding Thrombocytopenic Patients with Hematological Malignancies.
Am J Hematol.
Accepted Author Manuscript.
https://doi.
org/10.
1002/ajh.
26403

Leave a message here